VANCOUVER, BC, Oct. 12, 2021 /CNW/ - NeutriSci International
Inc. ("NeutriSci" or the "Company") (TSXV: NU)
(OTCQB: NRXCF) (FRANKFURT: 1N9),
an innovative technology company developing products, licencing,
IP, and technology for B2B partnerships and the nutraceutical
industry, is pleased to provide the following update.
Tabletz: Production for packaging needed for the
most recent Tabletz order is underway at the Company's partner
facilities in Asia. While there
continues to be supply chain challenges across every industry, the
Company and its partners have made arrangements to ensure the
packaging material needed to complete the order will be received in
the facility on time. Processes to produce the Tabletz products are
underway in North America. The
product is still on schedule for shipping in mid-November. Tabletz
LLC intends to have the completed product in Japan and out for distribution with its
distribution partners for December. Further details on distribution
partners will follow.
Cryopharm: Manufacturing of the first trial run with
its Michigan partner Red Bud has been completed. The initial product
run included gummies and the Marbl line of products. Red Bud has distribution in 275 locations. They
own licences for infusion, grow, extraction, sales, and
distribution. Scaling up on production to accommodate Red Bud's distribution network has begun. The
Company is expected to realize revenue from its licencing
arrangement with Cryopharm in Q4 2021. Cryopharm's Washington partner has begun production on the
Marbl Line with expectation for it to be on the shelf in the next
45 days. The Company is expected to realize revenue from its
licencing arrangement with Cryopharm in Q4 2021. Cryopharm has
finalized a contract with an Oklahoma group. Cryopharm will be having
meetings related to production and product roll out in the coming
week. Once the production begins, the Company will receive
licencing revenue from that as well. Timing on the start of
production is unknown at this time.
Neuenergy: The Company has completed its latest
production of tablets for the Neuenergy line. The latest production
run will be making its way to its national distribution partner,
ANB. ANB will be placing the product into its distribution channel
across Canada. Some of the ANB
retailers include Overwaitea, McKesson, Sobey's Safeway,
Pharmasave, Guardian, Remedy's RX. The Company also intends to
launch a bulk package containing 36 tabs and a refillable stick in
Q4 2021. Sales for the bulk product will begin on the Company's
website with an anticipated placement into the ANB distribution
network at a future date.
About NeutriSci International Inc.
NeutriSci specializes in the innovation, production, and
formulation of nutraceutical products. Established in 2009,
NeutriSci's is building sustainable sales models with Convenience,
Chain Drug, and Mass Market and Supermarket retailers for its
products offering co-branding as well as private label
opportunities and contract manufacturing services. For more
information, please visit: www.neutrisci.com.
On Behalf of the Board of Directors of
NEUTRISCI INTERNATIONAL INC.
Glen Rehman
CEO
Tel: (403) 264-6320
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accept responsibility for the adequacy or accuracy of
this release.
This news release may include forward-looking statements that
are subject to risks and uncertainties. All statements within,
other than statements of historical fact, are to be considered
forward-looking. Although the Company believes the
expectations expressed in such forward-looking statements are based
on reasonable assumptions, such statements are not guarantees of
future performance and actual results or developments may differ
materially from those in forward-looking statements. Factors
that could cause actual results to differ materially from those in
forward-looking statements include market prices, continued
availability of capital and financing, and general economic, market
or business conditions. There can be no assurances that such
statements will prove accurate and, therefore, readers are advised
to rely on their own evaluation of such uncertainties. We do
not assume any obligation to update any forward-looking statements
except as required under the applicable laws.
Statements in this press release have not been evaluated by
the Food and Drug Administration. Products or ingredients are
not intended to diagnose, treat, cure, or prevent any
disease.
SOURCE NeutriSci International Inc.